EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer

Anri Inaki, Atsushi Mizokami, Hiroshi Wakabayashi, Kouji Izumi, Yoshifumi Kadono, Tadashi Toyama, Shizuko Takahara, Toshinori Murayama, Seigo Kinuya

Annals of Nuclear Medicine · 2024-08 · 38 (8) · 587-595

DOI: 10.1007/s12149-024-01931-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Nuclear Medicine, online erschienen am 16.05.2024. Verfasst von Anri Inaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa-Shi, Ishikawa, 920-8641, Japan. henri@staff.kanazawa-u.ac.j…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Gallium Radioisotopes, Gallium Isotopes, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Telix Pharmaceuticals, Kanazawa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron emission tomography imaging using gallium-68 ( 68 Ga)-PSMA-11 has been shown to have a favorable safety and tolerability profile and high diagnostic performance. The study evaluates the safety and pharmacokinetics of 68 Ga-PSMA-11 in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer.

Methods

This single arm study enrolled Japanese patients with primary PC ( n = 3), suspected recurrent PC following radical prostatectomy ( n = 4), or suspected recurrent PC following radical radiotherapy ( n = 3). All patients received a single intravenous dose of 68 Ga-PSMA-11 2.0 MBq/kg (±10%) followed by PSMA PET imaging and safety and pharmacokinetic evaluations. Based on the blood concentrations of 68 Ga-PSMA-11 and the radioactivity distribution rate in each organ/tissue, the absorbed doses in major organs/tissues and the whole-body effective dose were calculated by the Medical Internal Radiation Dose method.

Results

Ten patients were enrolled. Mean age was 73.3 ± 4.8 years, and median prostate-specific antigen was 8.250 ng/mL. Five patients (50%) experienced a total of 6 adverse events, and no grade ≥ 2 adverse events or serious adverse events were reported. No clinically significant changes in vital signs, haematology parameters, or blood chemistry or ECG abnormalities were observed. The estimated whole body effective dose of 68 Ga-PSMA-11 (mean ± standard deviation) was 2.524 × 10 –2 ± 2.546 × 10 –3 mSv/MBq. Time to maximum concentration (1.16 × 10 –4 ± 1.3 × 10 –5 % ID/mL) in whole blood was 2.15 ± 0.33 min.

Conclusions

68 Ga-PSMA-11 has a favourable safety and tolerability profile in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer, which is comparable to previous observations in other populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGallium RadioisotopesGallium IsotopesPositron Emission Tomography Computed TomographyEdetic AcidOligopeptidesHumansMaleAgedMiddle AgedRecurrenceNeoplasm Recurrence, LocalJapanEast Asian People

Stichwörter der Autor:innen

68Ga-PSMA-11PSMA PETPositron emission imaging (PET)Prostate cancerProstate-specific membrane antigen (PSMA)

Substanzen

Gallium Radioisotopesgallium 68 PSMA-11Gallium IsotopesEdetic AcidOligopeptides

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa-Shi, Ishikawa, 920-8641, Japan. henri@staff.kanazawa-u.ac.jp.
  • Department of Integrative Cancer Therapy and Urology, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa-Shi, Ishikawa, 920-8641, Japan.
  • Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa-Shi, Ishikawa, 920-8641, Japan.
  • Innovative Clinical Research Center, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa-Shi, Ishikawa, 920-8641, Japan.
  • Department of Clinical Development, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa-Shi, Ishikawa, 920-8641, Japan.

Förderung

  • Telix Pharmaceuticals
  • Kanazawa University

Zitieren

APA

Inaki, A., Mizokami, A., Wakabayashi, H., Izumi, K., Kadono, Y., Toyama, T., Takahara, S., Murayama, T., & Kinuya, S. (2024). Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer. Annals of Nuclear Medicine, 38(8), 587-595. https://doi.org/10.1007/s12149-024-01931-7

Vancouver

Inaki A, Mizokami A, Wakabayashi H, Izumi K, Kadono Y, Toyama T, et al. Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer. Annals of Nuclear Medicine. 2024;38(8):587-595. doi:10.1007/s12149-024-01931-7

BibTeX
@article{Inaki2024,
  author = {Inaki, Anri and Mizokami, Atsushi and Wakabayashi, Hiroshi and Izumi, Kouji and Kadono, Yoshifumi and Toyama, Tadashi and Takahara, Shizuko and Murayama, Toshinori and Kinuya, Seigo},
  title = {Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer},
  journal = {Annals of Nuclear Medicine},
  year = {2024},
  volume = {38},
  number = {8},
  pages = {587--595},
  doi = {10.1007/s12149-024-01931-7}
}
Kostenlos starten →